MENU

STOK Stock Stoke Therapeutics (STOK, $12.76) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 14, 2024

A.I.dvisor
at Tickeron.com
10/15/24
Loading...
STOK - Stoke Therapeutics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $12.76
Daily change: +$0.92 (+7.77%)
Daily volume: 792.3K
Industry: Biotechnology
This is a Bullish indicator signaling STOK's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 50 similar cases where STOK's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

STOK in upward trend: price may jump up because it broke its lower Bollinger Band on September 23, 2024

STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where STOK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STOK's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on October 14, 2024. You may want to consider a long position or call options on STOK as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 14, 2024. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

STOK moved below its 50-day moving average on September 20, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for STOK crossed bearishly below the 50-day moving average on September 24, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.664) is normal, around the industry mean (12.594). P/E Ratio (0.000) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). STOK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (38.911) is also within normal values, averaging (224.025).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
STOK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the research and development of treatments for genetic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
45 Wiggins Avenue
Phone
+1 781 430-8200
Employees
110
Web
https://www.stoketherapeutics.com